Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Cigna Group, consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Current insurance and contractholder liabilities	5,388)	5,477)	5,616)	5,788)	5,514)	7,352)	7,539)	7,166)	5,385)	6,095)	5,654)	5,673)	5,318)	5,917)	5,850)	5,743)	5,308)	5,223)	5,060)	5,030)
Pharmacy and other service costs payable	28,465)	28,801)	27,503)	24,284)	19,815)	19,320)	18,617)	17,609)	17,070)	16,676)	16,432)	15,235)	15,309)	14,705)	14,470)	13,762)	13,347)	12,539)	11,856)	10,797)
Accounts payable	9,294)	8,515)	9,275)	8,118)	8,553)	7,673)	8,072)	7,360)	7,775)	6,870)	7,142)	6,632)	6,655)	5,659)	5,647)	5,640)	5,478)	5,327)	5,413)	5,585)
Accrued expenses and other liabilities	9,387)	8,920)	9,003)	8,857)	9,955)	9,668)	8,499)	9,174)	8,006)	7,986)	7,742)	7,833)	7,322)	7,356)	7,212)	7,921)	8,515)	7,153)	7,991)	7,585)
Short-term debt	3,035)	2,572)	1,717)	1,715)	2,775)	3,046)	4,618)	3,418)	2,993)	3,488)	2,397)	2,173)	2,545)	2,703)	1,532)	404)	3,374)	6,449)	4,750)	4,340)
Liabilities of businesses held for sale	2,410)	2,775)	2,259)	3,215)	2,104)	—)	—)	—)	—)	—)	5,851)	6,116)	6,423)	—)	—)	—)	—)	7,195)	7,109)	7,043)
Current liabilities	57,979)	57,060)	55,373)	51,977)	48,716)	47,059)	47,345)	44,727)	41,229)	41,115)	45,218)	43,662)	43,572)	36,340)	34,711)	33,470)	36,022)	43,886)	42,179)	40,380)
Non-current insurance and contractholder liabilities	10,254)	10,573)	10,449)	10,641)	10,904)	11,286)	11,575)	11,790)	11,481)	11,655)	11,777)	12,167)	12,563)	16,576)	16,665)	16,424)	16,844)	16,213)	16,064)	15,838)
Deferred tax liabilities, net	6,975)	6,794)	6,953)	7,029)	7,173)	7,480)	7,594)	7,707)	7,751)	7,777)	8,014)	8,110)	8,346)	8,832)	8,867)	8,832)	8,939)	9,142)	9,170)	9,066)
Other non-current liabilities	3,215)	3,033)	3,538)	3,653)	3,441)	2,932)	2,575)	2,692)	3,142)	3,179)	3,175)	3,346)	3,762)	4,261)	4,330)	4,485)	4,629)	4,552)	4,775)	4,519)
Long-term debt	28,937)	30,230)	30,175)	31,053)	28,155)	28,094)	28,115)	29,124)	28,100)	28,090)	30,984)	31,013)	31,125)	31,609)	31,606)	31,568)	29,545)	29,537)	31,774)	32,147)
Separate account liabilities	7,278)	7,651)	7,431)	7,416)	7,430)	7,028)	7,324)	7,340)	7,278)	7,260)	7,495)	8,148)	8,337)	9,150)	9,261)	9,088)	9,086)	8,616)	8,261)	7,640)
Liabilities of businesses held for sale, non-current	—)	—)	—)	—)	591)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Non-current liabilities	56,659)	58,281)	58,546)	59,792)	57,694)	56,820)	57,183)	58,653)	57,752)	57,961)	61,445)	62,784)	64,133)	70,428)	70,729)	70,397)	69,043)	68,060)	70,044)	69,210)
Total liabilities	114,638)	115,341)	113,919)	111,769)	106,410)	103,879)	104,528)	103,380)	98,981)	99,076)	106,663)	106,446)	107,705)	106,768)	105,440)	103,867)	105,065)	111,946)	112,223)	109,590)
Redeemable noncontrolling interests	—)	—)	—)	—)	107)	64)	62)	78)	66)	50)	45)	55)	54)	56)	51)	59)	58)	59)	34)	35)
Common stock, $0.01 par value per share	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)	4)
Additional paid-in capital	31,288)	31,186)	31,048)	30,292)	30,669)	30,563)	30,436)	30,332)	30,233)	29,395)	29,930)	29,736)	29,574)	29,077)	29,403)	29,254)	28,975)	28,777)	28,699)	28,554)
Accumulated other comprehensive loss	(2,341)	(2,163)	(2,442)	(2,324)	(1,864)	(2,119)	(1,878)	(1,769)	(1,395)	(2,009)	(2,080)	(1,492)	(884)	(1,153)	(1,077)	(1,231)	(861)	(541)	(788)	(1,527)
Retained earnings	43,519)	42,480)	42,132)	40,978)	41,652)	40,982)	39,936)	38,841)	37,874)	37,041)	34,626)	33,420)	32,593)	31,803)	30,513)	29,389)	28,575)	24,440)	23,052)	21,298)
Treasury stock, at cost	(31,437)	(29,412)	(29,410)	(27,769)	(24,238)	(23,739)	(23,053)	(22,906)	(21,844)	(19,390)	(16,588)	(15,581)	(14,175)	(12,316)	(10,134)	(9,267)	(6,372)	(4,648)	(3,601)	(3,250)
Shareholders’ equity	41,033)	42,095)	41,332)	41,181)	46,223)	45,691)	45,445)	44,502)	44,872)	45,041)	45,892)	46,087)	47,112)	47,415)	48,709)	48,149)	50,321)	48,032)	47,366)	45,079)
Other noncontrolling interests	210)	203)	195)	169)	21)	11)	19)	16)	13)	42)	30)	22)	18)	12)	7)	6)	7)	7)	5)	7)
Total equity	41,243)	42,298)	41,527)	41,350)	46,244)	45,702)	45,464)	44,518)	44,885)	45,083)	45,922)	46,109)	47,130)	47,427)	48,716)	48,155)	50,328)	48,039)	47,371)	45,086)
Total liabilities and equity	155,881)	157,639)	155,446)	153,119)	152,761)	149,645)	150,054)	147,976)	143,932)	144,209)	152,630)	152,610)	154,889)	154,251)	154,207)	152,081)	155,451)	160,044)	159,628)	154,711)

Current insurance and contractholder liabilities: The current insurance and contractholder liabilities showed moderate fluctuations over the periods. Starting at 5,030 million USD in March 2020, the values peaked at 7,539 million USD in June 2023 before declining to 5,388 million USD by December 2024, indicating variability without a clear long-term increasing or decreasing trend.
Pharmacy and other service costs payable: These costs steadily increased from 10,797 million USD in March 2020 to a high of 28,801 million USD by September 2024, representing a significant upward trend. A slight decline occurred in December 2024, but the overall trend shows consistent growth, likely reflecting rising pharmacy and related service expenses over time.
Accounts payable: Accounts payable experienced a gradual increase from 5,585 million USD in March 2020 to 9,294 million USD in December 2024. Despite some period-to-period fluctuations, the trend indicates an overall upward movement, potentially reflecting increased purchasing or operational scale.
Accrued expenses and other liabilities: This category exhibited moderate variation with values between 7,153 and 9,668 million USD, peaking around September 2023 and then varying slightly thereafter. The fluctuations suggest changes in short-term obligations but no sustained directional trend.
Short-term debt: Short-term debt showed high volatility, starting at 4,340 million USD in March 2020, falling sharply during 2021 to lows around 404 million USD, then recovering somewhat in 2023 and again decreasing by 2024. This indicates shifting reliance on short-term borrowing facilities.
Liabilities of businesses held for sale: This liability presented intermittent data but generally declined from above 7,000 million USD in early 2020 to lower levels by 2024, corresponding to divestitures or reclassification of assets.
Current liabilities: Current liabilities showed an overall rising trend from about 40,380 million USD in March 2020 to 57,979 million USD by December 2024. Some fluctuations in 2022 and 2023 were observed, but the general upward movement suggests increased short-term financial obligations.
Non-current insurance and contractholder liabilities: These non-current liabilities decreased steadily from 15,838 million USD in March 2020 to approximately 10,254 million USD by December 2024, indicating a reduction in long-term insurance and contractholder obligations over the observed period.
Deferred tax liabilities, net: Deferred tax liabilities mostly decreased over time from 9,066 million USD in March 2020 to 6,975 million USD by June 2024, with a slight increase in the last reported period. This suggests gradual reduction of tax obligations reflected in deferred liabilities.
Other non-current liabilities: This category showed a declining trend from 4,519 million USD in March 2020 to lower levels around 3,215 million USD in December 2024, indicating a reduction in other long-term obligations.
Long-term debt: Long-term debt remained relatively stable around 30,000 to 32,000 million USD through most of the periods but showed a slight decline toward the end of the observation, dropping to 28,937 million USD in December 2024. This suggests modest debt reduction efforts over time.
Separate account liabilities: Separate account liabilities showed a slight downward trend moving from approximately 7,640 million USD in early 2020 to 7,278 million USD in December 2024, reflecting minor changes in segregated account obligations.
Non-current liabilities: Overall, non-current liabilities decreased from about 69,210 million USD in March 2020 to 56,659 million USD in December 2024. This steady decline indicates a reduction in long-term financial obligations.
Total liabilities: Total liabilities peaked around mid-2024 near 115,341 million USD but generally fluctuated around 103,000 to 114,000 million USD during the period, with a slight increase towards the end, suggesting varying but stable overall liability levels.
Redeemable noncontrolling interests: This value remained minor and mostly stable, with some fluctuations and missing data at the end of the timeline, indicating limited impact on the capital structure.
Common stock: Common stock par value remained constant at 4 million USD throughout, reflecting no changes in share issuance or par value adjustments.
Additional paid-in capital: Additional paid-in capital gradually increased from 28,554 million USD in March 2020 to 31,288 million USD by December 2024, showing consistent incremental equity financing or retained earnings capitalization.
Accumulated other comprehensive loss: This item increased in absolute loss from -1,527 million USD to around -2,341 million USD, showing increasing unrealized losses or other comprehensive losses over time, with some fluctuations indicating market or valuation impacts.
Retained earnings: Retained earnings steadily increased from 21,298 million USD in March 2020 to 43,519 million USD by December 2024, reflecting sustained profitability and accumulation of earnings over the periods.
Treasury stock, at cost: Treasury stock values deepened the negative balance from -3,250 million USD to -31,437 million USD, indicating significant ongoing repurchase of shares, thus reducing outstanding equity.
Shareholders’ equity: Equity fluctuated, starting at 45,079 million USD in March 2020, peaking around 46,223 million USD in December 2023, then declining to 41,033 million USD by December 2024, showing some reduction in net equity despite overall earnings growth.
Other noncontrolling interests: Other noncontrolling interests increased from low single digits to over 200 million USD by December 2024, showing increased minority interests in subsidiaries.
Total equity: Total equity followed a similar pattern to shareholders' equity, with a peak near 46,244 million USD in December 2023 before falling to 41,243 million USD by December 2024, indicating some equity reduction in the final periods.
Total liabilities and equity: The combined total of liabilities and equity rose initially from about 154,711 million USD in March 2020 to a peak of approximately 157,639 million USD by September 2024, then slightly decreased by the end of 2024, showing overall stable asset base with minor fluctuations.

Download chart

Cigna Group (NYSE:CI)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data